FY2026 EPS Estimates for Novartis Decreased by Analyst

Novartis AG (NYSE:NVS) – Equities researchers at Erste Group Bank reduced their FY2026 earnings per share (EPS) estimates for shares of Novartis in a research note issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $8.90 for the year, down from their previous estimate of $9.01. The consensus estimate for Novartis’ current full-year earnings is $8.75 per share.

Several other equities analysts have also recently weighed in on the stock. Morgan Stanley raised their target price on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research note on Thursday, March 26th. Weiss Ratings downgraded shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Trading Up 2.8%

Novartis stock opened at $153.82 on Monday. The stock has a market cap of $293.51 billion, a P/E ratio of 22.04, a PEG ratio of 2.58 and a beta of 0.45. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. Novartis has a 1 year low of $112.34 and a 1 year high of $170.46. The firm’s 50 day moving average price is $151.61 and its 200-day moving average price is $151.88.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The company had revenue of $14.95 billion for the quarter.

Institutional Investors Weigh In On Novartis

Hedge funds have recently bought and sold shares of the business. Madson Wealth Advisors Inc grew its stake in shares of Novartis by 11.3% in the 2nd quarter. Madson Wealth Advisors Inc now owns 7,299 shares of the company’s stock worth $1,144,000 after buying an additional 740 shares in the last quarter. Evolution Wealth Management Inc. raised its position in shares of Novartis by 552.0% during the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after buying an additional 138 shares in the last quarter. CV Advisors LLC purchased a new stake in shares of Novartis during the 2nd quarter valued at about $596,000. Summitry LLC lifted its holdings in shares of Novartis by 16.3% in the 2nd quarter. Summitry LLC now owns 2,464 shares of the company’s stock valued at $386,000 after acquiring an additional 346 shares during the last quarter. Finally, SOA Wealth Advisors LLC. lifted its holdings in shares of Novartis by 4,316.2% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 14,750 shares of the company’s stock valued at $2,312,000 after acquiring an additional 14,416 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Key Stories Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis topped Q2 earnings estimates, posting $2.41 per share versus $2.17 expected, while revenue also came in above forecasts. The beat was driven by strong demand for key drugs and lower-than-expected costs. Novartis earnings report
• Positive Sentiment: The company returned to sales growth in Q2 as newer medicines offset generic pressure, with strength in cancer and multiple sclerosis treatments helping support results. Reuters Q2 profit story
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests confidence that growth from newer products can continue despite headwinds. Zacks earnings recap
• Neutral Sentiment: Investors are also watching upcoming late-stage trial readouts in the second half of the year, which could influence the stock’s longer-term valuation narrative. Reuters pipeline valuation story
• Negative Sentiment: Ongoing generic competition and a sharp drop in Entresto sales remain major headwinds, and investors may worry about pressure on older blockbusters. Invezz Entresto sales drop story

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.